Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T-cell Acute Lymphoblastic Leukemia: early-phase trial registry
7 of 7 indexed T-cell Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 7 currently recruiting · #2,497 of 28,707 conditions by registered trial count
T-cell Acute Lymphoblastic Leukemia: 7 US clinical trials tracked, 7 recruiting.
T-cell Acute Lymphoblastic Leukemia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 2 of these trials.
Enrollment posture brief
Registry condition t-cell-acute-lymphoblastic-leukemia
OPEN 7 | RECR 100% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
T-cell Acute Lymphoblastic Leukemia lists 7 open slots (100% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T-cell Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T-cell Acute Lymphoblastic Leukemia is recruiting above its size-band peers.
7 of 7 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates T-cell Acute Lymphoblastic Leukemia research.
Baylor College of Medicine accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most T-cell Acute Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
T-cell Acute Lymphoblastic Leukemia research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen
NCT06514794
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06390319
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Baylor College of Medicine
NCT03081910
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
New York Medical College
NCT04972942
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Baylor College of Medicine
NCT03690011
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
NCT06561074
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
NCT05289687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on T-cell Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T-cell Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T-cell Acute Lymphoblastic Leukemia page
7 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 T-cell Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most T-cell Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T-cell Acute Lymphoblastic Leukemia condition card totals 7 registered trials; most-linked intervention CD7.CAR/28zeta CAR T cells; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.